Last reviewed · How we verify

Dalian Zhen-Ao Bio-Tech Co., Ltd. — Portfolio Competitive Intelligence Brief

Dalian Zhen-Ao Bio-Tech Co., Ltd. pipeline: 0 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. China Academy of Chinese Medical Sciences · 1 shared drug class
  2. Cooperative Study Group A for Hematology · 1 shared drug class
  3. Daiichi Sankyo Co., Ltd. · 1 shared drug class
  4. Genuine Research Center, Egypt · 1 shared drug class
  5. GlaxoSmithKline · 1 shared drug class
  6. Guangdong Raynovent Biotech Co., Ltd · 1 shared drug class
  7. Hoffmann-La Roche · 1 shared drug class
  8. National Institute for Public Health and the Environment (RIVM) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dalian Zhen-Ao Bio-Tech Co., Ltd.:

Cite this brief

Drug Landscape (2026). Dalian Zhen-Ao Bio-Tech Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dalian-zhen-ao-bio-tech-co-ltd. Accessed 2026-05-16.

Related